Sirtex Receives Expanded CE Mark Approval for SIR-Spheres Y-90 Resin Microspheres
Broadened indication increases access to liver cancer treatment across Europe and CE-marked…
NanoNewron Awarded $2.5 Million in NIH STTR Phase 2 Grant to Advance its Innovative NN-840 Alzheimers Disease Program
The $2.5 Million in NIH STTR Phase 2 Grant allows NanoNewron to…
KFSHRC Conducts 48% of Clinical Trials in Saudi Arabia During the First Half of 2025
RIYADH, Saudi Arabia, Sept. 10, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist…
Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by…
Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd…
Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism
September 06, 2025 14:30 ET | Source: BridgeBio Pharma, Inc. - 80%…
Zai Lab Announces Approval of TIVDAK for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today…
Berlin Heals Holding AG Successfully Raises Over 5Million USD Round for Advancing New Less Invasive Approaches
ZUG, Switzerland, Sept. 1, 2025 /PRNewswire/ -- Berlin Heals Holding AG, a…
Novo Nordisks Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas
Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater…
Angelalign Technology Announces First-Half 2025 Results While Increasing Investments in Legal, Supply Chain and Data Security
SAN CLEMENTE, Calif., Aug. 26, 2025 /PRNewswire/ -- Angelalign Technology Inc. ("Angel"…